Anti-IL13 human antibodies
The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
1. An isolated anti-IL-13 antibody, or antigen-binding fragment thereof, comprising H-CDR1, H-CDR2 and H-CDR3 selected from (i)-(ii):
(i) SEQ ID NO: 6, SEQ ID NO:8, and SEQ ID NO: 9, respectively; and
(ii) SEQ ID NO: 7, SEQ ID NO:8, and SEQ ID NO: 10, respectively;
and comprising L-CDR1, L-CDR2 and L-CDR3 selected from (iii)-(v):
(iii) SEQ ID NO: 16. SEQ ID NO: 19, and SEQ ID NO: 20, respectively;
(iv) SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21, respectively; and
(v) SEQ ID NO: 18. SEQ ID NO: 19, and SEQ ID NO: 22, respectively.
2. The antibody according to claim 1 which comprises a heavy chain variable region having an amino acid sequence selected from any one of SEQ ID NO: 23, 27, 31 and 35.
3. The antibody according to claim 1 which comprises a light chain variable region having the amino acid sequence selected from any one of SEQ ID NO: 25, 29, 33 and 37.
4. An isolated anti-IL-13 antibody, or antigen-binding fragment thereof, comprising a heavy chain variable region having an amino acid sequence selected from any one of SEQ ID NO: 23, 27, 31 and 35, and a light chain variable region having the amino acid sequence selected from any one of SEQ ID NO: 25, 29, 33 and 37.
5. The antibody according to claim 4 comprising a heavy chain variable region according to SEQ ID NO: 23 and a light chain variable region according to SEQ ID NO:25.
6. The antibody according to claim 4 comprising a heavy chain variable region according to SEQ ID NO: 27 and a light chain variable region according to SEQ ID NO: 29.
7. The antibody according to claim 4 comprising a heavy chain variable region according to SEQ ID NO: 31 and a light chain variable region according to SEQ ID NO: 33.
8. The antibody according to claim 4 comprising a heavy chain variable region according to SEQ ID NO: 35 and a light chain variable region according to SEQ ID NO: 37.
9. The antibody according to claim 1 which is an IgGI or an IgG4.
10. A pharmaceutical composition comprising an antibody or functional fragment thereof according to claim 1 and a pharmaceutically acceptable carrier or excipient therefore.
11. The antibody, or antigen-binding fragment, of claims 1 wherein the antibody is a human antibody, a humanized antibody, a Fab, or a scFV.